Biocept to Begin COVID-19 Testing
"While we continue to focus primarily on providing actionable results for patients diagnosed with cancer, we are pleased to support our clients and public health efforts by expanding our offerings to include COVID-19 testing. I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," said
In preparation to offer COVID-19 testing, an unapproved version of a test website page was inadvertently posted to the Company's website by a third-party website consultant. This unapproved test website page contained certain inaccuracies related to billing matters and should be disregarded.
For physician questions, please contact customerservice@biocept.com.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the exact time that we will begin accepting physician-ordered COVID-19 testing requests for processing, and our ability to enter into additional agreements to accept COVID-19 patient samples, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
Media Contact:
CORE IR
julesa@coreir.com
917-885-7378
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-begin-covid-19-testing-301038660.html
SOURCE